Top

Published in:

Open Access 01-10-2017 | Review

A Practical Approach to Managing Hypoactive Sexual Desire Disorder in Women with Diabetes

Authors: Charmaine Rochester-Eyeguokan, Lisa Meade

Published in: Diabetes Therapy | Issue 5/2017

Abstract

Female sexual dysfunction (FSD) is highly prevalent in women with diabetes mellitus (DM), yet it remains unaddressed, undiagnosed, and untreated. Hypoactive sexual desire disorder (HSDD) is the most common complaint among women with FSD, but there is a paucity of research into its multifactorial etiology. Flibanserin is the only therapy approved by the US Food and Drug Administration for treating acquired, generalized HSDD in premenopausal women. Women with DM diagnosed with HSDD may require a multidisciplinary approach for optimal management.

Enzlin P, Rosen R, Wiegel M, et al. Sexual dysfunction in women with type 1 diabetes. Diabetes Care. 2009;32:780–5.CrossRefPubMedPubMedCentral

Doruk H, Akbay E, Cayan S, et al. Effect of diabetes mellitus on female sexual function and risk factors. Arch Androl. 2005;51:1–6.CrossRefPubMed

Enzlin P, Mathieu C, Van den Bruel A, et al. Prevalence and predictors of sexual dysfunction in patients with type 1 diabetes. Diabetes Care. 2003;26:409–14.CrossRefPubMed

Mimoun S, Wylie K. Female sexual dysfunctions: definitions and classification. Mauritas. 2009;63:116–8.

Clayton AH. The pathophysiology of hypoactive sexual desire disorder in women. Int J Gynaecol Obstet. 2010;110:7–11.CrossRefPubMed

Goldstein I, Kim NN, Clayton AH, et al. Hypoactive sexual desire disorder: International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Mayo Clin Proc. 2017;92(1):114–28.CrossRefPubMed

Kingsberg SA, Iglesia CB, Kellogg S, et al. Handbook on female sexual health and wellness. Association of Reproductive Health Professionals. http://www.arhp.org/Publications-and-Resources/Clinical-Practice-Tools/Handbook-On-Female-Sexual-Health-And-Wellness ARHP 2011:1–24. Accessed 31 Aug 2017.

Miocic J, Car N, Metelko Z. Sexual dysfunction in women with diabetes mellitus. Diabetologia Croatica. 2008;37:35–42.

Palacios S, Casta R, Grazziotin A. Epidemiology of female sexual dysfunction. Mauritas. 2009;63:119–23.

10.

Buster JE. Managing female sexual dysfunction. Fertil Steril. 2013;100:905–15.CrossRefPubMed

11.

Clayton AH, Goldfischer ER, Goldstein I, et al. Validation of the decreased sexual desire screener (DSDS): a brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD). J Sex Med. 2009;6:730–8.CrossRefPubMed

12.

US FDA. FDA approves first treatment for sexual desire. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm458734.htm. Accessed 19 June 2017.

13.

Katz M, Derogatis LR, Ackerman R, et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med. 2013;10(7):1807–15.CrossRefPubMed

14.

Goldfischer ER, Breaux J, Katz M, et al. Continued efficacy and safety of flibanserin in premenopausal women with hypoactive sexual desire disorder results from a randomized withdrawal trial. J Sex Med. 2011;8:3160–72.CrossRefPubMed

15.

Jaspers L, Feys F, Bramer WM, et al. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women, a systematic review and meta-analysis. JAMA Intern Med. 2016;176(4):453–62.CrossRefPubMed

16.

Woodis CB, McLendon AN, Muzyk AJ. Testosterone supplementation for hypoactive sexual desire disorder in women. Pharmacotherapy. 2012;32(1):38–53.CrossRefPubMed

17.

Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:3489–510.CrossRefPubMed

18.

Lodise NM. Hypoactive sexual desire disorder in women: treatment options beyond testosterone and approaches to communication with patients on sexual health. Pharmacotherapy. 2013;33(4):411–21.CrossRefPubMed

19.

Safarinejad MR, Hosseini SY, Asgari MA, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women. BJU Int. 2010;106:832–9.CrossRefPubMed

Title: A Practical Approach to Managing Hypoactive Sexual Desire Disorder in Women with Diabetes
Authors: Charmaine Rochester-Eyeguokan
Lisa Meade
Publication date: 01-10-2017
Publisher: Springer Healthcare
Published in: Diabetes Therapy / Issue 5/2017
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI: https://doi.org/10.1007/s13300-017-0313-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

A Practical Approach to Managing Hypoactive Sexual Desire Disorder in Women with Diabetes

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2017

Efficacy and Time Sensitivity of Amniotic Membrane treatment in Patients with Diabetic Foot Ulcers: A Systematic Review and Meta-analysis

Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S)

Improved Glycemic Control in a Patient Group Performing 7-Point Profile Self-Monitoring of Blood Glucose and Intensive Data Documentation: An Open-Label, Multicenter, Observational Study

Erratum to: Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes

Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study

Visceral Adipose Tissue as a Risk Factor for Diabetes Mellitus in Patients with Chronic Pancreatitis: A Cross-sectional, Observational Study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page